Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Free Cash Flow (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Free Cash Flow data on record, last reported at -$4.9 million in Q3 2025.

  • For Q3 2025, Free Cash Flow rose 18.92% year-over-year to -$4.9 million; the TTM value through Sep 2025 reached -$17.3 million, up 17.92%, while the annual FY2024 figure was -$18.9 million, 0.08% changed from the prior year.
  • Free Cash Flow reached -$4.9 million in Q3 2025 per GANX's latest filing, up from -$5.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$2.2 million in Q3 2021 and bottomed at -$6.1 million in Q3 2024.
  • Average Free Cash Flow over 5 years is -$4.2 million, with a median of -$4.0 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: plummeted 663.78% in 2021, then skyrocketed 38.95% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$4.2 million in 2021, then increased by 5.86% to -$3.9 million in 2022, then tumbled by 44.62% to -$5.7 million in 2023, then surged by 38.95% to -$3.5 million in 2024, then tumbled by 42.56% to -$4.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$4.9 million in Q3 2025, -$5.1 million in Q2 2025, and -$3.8 million in Q1 2025.